Recent Updates
Recently added Catalysts
VNRX Neutral Sentiment

Nu.Q® NETs brochure

Monday, November 27, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the Nu.Q® NETs brochure and highlights related articles about the prognostic value of the Nu.Q® cancer test and its relevance to sepsis transcriptional states. It invites readers to subscribe for updates on Volition products and provides links for investor updates and press releases.
Price reaction · baseline $15.52 (2023-11-27T14:56:00.000Z) · hit during market hours · 1 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-1%

Market Sentiment Analysis

Full Press Release Details

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the Nu.Q® NETs brochure about?

The Nu.Q® NETs brochure discusses the prognostic value of the Nu.Q® cancer test.

Are there related articles available?

Yes, the article mentions related articles on the Nu.Q® cancer test and sepsis.

How can I receive updates on Volition products?

You can subscribe for updates on Volition products through the provided link.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare Nu.Q® cancer test sepsis prognostic value
Last updated: Nov 27, 2023

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk